COPENHAGEN, Sept 24 (Reuters) - Danish pharmaceutical group Lundbeck said on Monday it licensed the European rights to the insomnia drug Circadin from Neurim Pharmaceuticals Ltd. Israel-based Neurim ...

For some, getting a good night's sleep remains elusive. Neurim Pharmaceuticals hopes to change all that with its new drug Circadin. Traditional sleeping pills have many side effects. Now an Israeli ...

EC approves change in primary insomnia treatment duration with Circadin from 3 to 13 weeks ...

Circadin is approved for longer use in patients with primary insomnia, aged 55 years or over.1 Following an extension to its current licence, doctors can now prescribe Circadin for a period of up to ...

If you're over 55 and have spent more than a few sleepless nights, you're not alone -- insomnia affects about half of all people over 55 -- but you may also be at increased risk for physical and ...

Lundbeck is celebrating the European launch of Circadin, a new, first-in-class sleep medication which the Danish firm says will offer “hope for thousands of sufferers of insomnia”. Lundbeck is ...

Circadin (R), currently approved for use in 33 countries, is a novel sleep aid indicated for treatment of primary insomnia. The latest approval in Australia by the TGA, was based on clinical studies ...

Circadin ® (prolonged release melatonin) licence extended to include treatment for up to 13 weeks¹ in patients with primary insomnia Dialogue with elderly patients Prescribing information The role of ...